Shanghai Healthcare Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 4
Average round size
info
The average size of a deal this fund participated in
$43M
Portfolio companies 4
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Clinical Trials
  • Therapeutics
  • Pharmaceutical
  • Health Care
  • Semiconductor

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Shanghai Healthcare Capital:
Typical Co-investors
Shanghai Healthcare Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Shanghai Healthcare Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Action Hero Ventures South Africa, Stellenbosch, Western Cape
Affirma Capital England, London, United Kingdom
Changrun Jinkong China, Guangdong, Shenzhen
Commonwealth's Opportunity Fund -
Crescat Capital Colorado, Denver, United States
Donghan International -
Haitong Securities China, Shanghai
HuaJin Securities China, Shanghai
Koerner Capital Louisiana, New Orleans, United States
leAD Sports & Health Tech Partners Berlin, Berlin, Germany
Moonstone Capital England, London, United Kingdom
Omega Pharmaceuticals England, London, United Kingdom
Predictive VC -
Rumford Bavaria, Germany, Munich
Seazen China, Guangxi, Zhongjiang
The Judd Leighton Foundation -
Yixin Touzi Beijing, Beijing, China
Zhangsheng Guquan China, Shanxi, Xinjiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ranok Therapeutics

$40M19 Aug 2021 Hangzhou, Zhejiang, China

Abbisko Therapeutics

Health Care
Pharmaceutical
Therapeutics
$123M07 Jan 2021 China, Shanghai

Immvira

Clinical Trials
$10M24 Sep 2020 Futian District, Guangdong Province

VeriSilicon Holdings

Cloud Computing
DSP
Manufacturing
Semiconductor
03 Sep 2018 Shanghai, China
News
Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline

– Ranok Therapeutics (Hangzhou) Co. Ltd. secured a $40m Series B funding round denominated in both U.S. dollars and Chinese yuan.
– The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors.
– To date, Ranok has raised the equivalent of over $50m in funding.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shanghai Healthcare Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: